Jeff Ruby had an epiphany at a doctor’s office. His father’s oncologist had just dropped the C-bomb: his father had an abdominal cancer that would kill him within two years.
Jeff remembers hearing his 54-year-old father ask, “How did I get this?” The answer to that question took Jeff somewhat by surprise: genetics and lifestyle choices.
Until that moment, Jeff wasn’t aware that this combination was a perfect recipe for cancer. After connecting the dots to his own DNA, he walked out of the doctor’s office concerned not only about his own future, but also about the future of millions of people whose lives could be affected by the power of knowledge.
El objetivo de esta jornada, como en anteriores ediciones, es crear un diálogo entre el mundo académico el ámbito empresarial y reflexionar sobre el papel estratégico del diseño en las empresas y en la sociedad. En esta edición se trata de conectar con empresas e instituciones del mundo de la salud para mostrar el potencial de las metodologías y las herramientas de diseño centrado en el paciente.
La fecha de celebración es el viernes 27 de mayo de 2016, a las 9:00h en el Mueso San Telmo de San Sebastian- Donostia.
A group of Icelandic researchers, part of an Amgen AMGN 1.02% unit called deCODE genetics, uncovered a rare and previously unknown genetic variation in some people that drastically reduces the risk of a heart attack and lowers cholesterol levels.
The race to develop a gene therapy for hemophilia just moved another few feet forward. Spark Therapeutics, which is one of several companies developing a treatment, is the latest to provide its first glimpse of clinical data in human patients.
The U.S. government wants to speed up development of wearable alcohol sensors; in that vein, today it announced the winners of a contest intended to stimulate innovation. The U.S. National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $200,000 first prize to San Francisco–based BACtrack, and a $100,000 second prize to Santa Barbara, California–based Milo Sensors. Both groups submitted prototypes of wrist wearables that detect traces of alcohol diffusing through the skin.
Just swallow a pill and it expands into a balloon in your stomach so you don’t feel hungry. No gastric bypass, no surgery required. Sounds magical, but Boston-based Allurion has created the only non-invasive gastric balloon for obesity.
Gastric balloons are nothing new, but you usually need anesthesia and a doctor to insert them. That makes the whole process expensive and prohibitive to anyone afraid of undergoing the knife just to lose some weight.
Allurion’s Elipse device makes the process more comfortable with one quick gulp.
La multinacional catalana de hemoderivados Grifols ha llegado a un acuerdo para adquirir el 20 % de la empresa estadounidense de diagnóstico Singulex por un importe de 50 millones de dólares (unos 44,2 millones de euros).
Grifols, que ha tomado esta participación a través de una ampliación de capital, tendrá asimismo un representante en el consejo de administración.
Singulex tiene su sede en Alameda, en el estado de California (EEUU), y ha desarrollado y patentado la tecnología de ultrasensibilidad SMC (Simple Molecular Counting), que tiene amplias aplicaciones en diagnóstico clínico y en el ámbito investigador.
La iniciativa cuenta con el apoyo del programa de impulso a la innovación tecnológica Gaitek.
Con el objetivo de mejorar la calidad de vida de los pacientes de enfermedades circulatorias, la empresa Bilbomatica, el Clúster GAIA y la Asociación Guipuzcoana de Anticoagulados trabajan en el desarrollo de un sistema tecnológico que permita hacer seguimiento de la evolución clínica de pacientes a tratamiento de anticoagulantes orales.
Los emprendedores españoles empiezan a apostar seriamente por la salud. Según datos de Startupxplore, la mayor comunidad online de startups en España y la segunda de Europa (9.000 empresas, 2.900 inversores y 550 aceleradoras), el número de nuevas compañías de este sector inscritas a su servicio aumentó un 53% en 2015 respecto al año anterior.
Se trata del segundo sector que más creció, solo superado por el deportivo. Hoy forman parte de esta red 168 pequeñas empresas relacionadas con la e-health. En esta categoría no entra la biotecnología, sector que maneja unas inversiones y tiempos de desarrollo mucho mayores.
From the patient’s perspective, the way that blood tests work today is not very different from how they worked 30 years ago: a blood sample taken at a doctor’s office gets sent to a lab somewhere and then a week or so later the results return.
Now, what if the entire lab could be put inside a device as simple as a cellphone that could process the same blood work in just 20 minutes using a single drop of blood?
